Andrew Lloyd ALA

💡TIP #3: if all spokespersons are media-trained, the delivery of your company messages will be consistent and stronger -> Interested in media training? See how ALA’s media training has helped our clients feel more confident and prepared for every interview

[ALA Client News] Cathpax roll-outs new radiation protection system Nova-X® across EMEA following very promising clinical results ala.associates/clinical/cat... #medtech #neuroradiology

[ALA Client News] BLEEDnFIRE Therapeutics launches with non-dilutive funding to advance first-in-class pan-indication therapy for rare bleeding disorders ala.associates/funding/blee... #hemophilia #innovation #hematology @inselgruppe.bsky.social @unibe.ch

[ALA Client News] Exciva appoints distinguished biopharma leader Mark Altmeyer as chairman of the board ala.associates/appointment/... #alzheimers #neuropsychiatric #biopharma

[ALA Client News] Robocath completes enrollment in First-In-Human (FIH) study of next-gen robotic platform in interventional cardiology ala.associates/clinical/rob... #robotics #cardiology #clinicaltrials

[ALA Client News] Exciva doses first patient in Phase 2/3 trial of Deraphan for agitation in Alzheimer’s disease and extends Series B round ala.associates/clinical/exc... #alzheimers #clinicaltrial #seriesB

[ALA Client News] Kahimmune Therapeutics signs agreement for scientific collaboration with @gustaveroussy.fr ala.associates/partnership/... #biotech #oncology

[ALA Client News] Kayentis and RWS join forces to improve data confidence in neuroscience clinical trials ala.associates/partnership/... #neuroscience #clinicaltrials #digitalhealth #pharma

[ALA Client News] Clean Cells and Naobios showcase complete end-to-end viral vaccines and vector solutions at BIO KOREA 2026 ala.associates/events/clean... #BIOKOREA2026

Celebrating our clients' media successes 🌟 1️⃣ @vygongroup.bsky.social in @lesechosfr.bsky.social. Acquired Stiletto®, boosting vascular access leadership. 2️⃣ PLL Therapeutics in @neurologylive.bsky.social. Positive stage I results of phase I/II trial in ALS. #PR #biotech #medtech

[ALA Client News] Perceptive eClinical and Kayentis partner to tackle increasing digital system complexity in global clinical trials ala.associates/partnership/... #clinicaltrials #digitalhealth #biotech #pharma

[ALA Client News] iPerf enrolls first patient in clinical trial of innovative dual-flow femoral arterial cannula for cardiopulmonary support ala.associates/clinical/ipe... @ap-hp.bsky.social #cardiovascular #cannula #medtech

[ALA Client News] Genoskin Showcases HypoSkin® Ex Vivo Platform at @sotoxicology.bsky.social Annual Meeting ala.associates/events/genos... #immunology #2026SOT

[ALA Client News] Bio‑Sourcing and Tiny Cargo join forces to develop oral delivery therapies of monoclonal antibodies using goat‑milk exosomes ala.associates/partnership/... #exosomes #biologics

Wishing you all a great year in 2026! 2025 has been a busy year for our clients with 67 news announcements, countless interviews and dozens of social media posts. As a result, more than 2,300 clippings! We thank our clients and partners for their trust. Kudos to the team for their achievements!